Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) - Net Assets

Latest as of September 2025: Rs2.53 Billion INR ≈ $27.34 Million USD

Based on the latest financial reports, Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) has net assets worth Rs2.53 Billion INR (≈ $27.34 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs2.99 Billion ≈ $32.34 Million USD) and total liabilities (Rs461.88 Million ≈ $5.00 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Jagsonpal Pharmaceuticals Limited to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Rs2.53 Billion
% of Total Assets	84.55%
Annual Growth Rate	6.68%
5-Year Change	96.79%
10-Year Change	143.94%
Growth Volatility	8.48

Jagsonpal Pharmaceuticals Limited - Net Assets Trend (2006–2025)

This chart illustrates how Jagsonpal Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. Also explore Jagsonpal Pharmaceuticals Limited assets under control for the complete picture of this company's asset base.

Annual Net Assets for Jagsonpal Pharmaceuticals Limited (2006–2025)

The table below shows the annual net assets of Jagsonpal Pharmaceuticals Limited from 2006 to 2025. For live valuation and market cap data, see how much is Jagsonpal Pharmaceuticals Limited worth.

Year	Net Assets	Change
2025-03-31	Rs2.40 Billion ≈ $25.95 Million	+28.04%
2024-03-31	Rs1.87 Billion ≈ $20.27 Million	+17.94%
2023-03-31	Rs1.59 Billion ≈ $17.18 Million	+21.42%
2022-03-31	Rs1.31 Billion ≈ $14.15 Million	+7.32%
2021-03-31	Rs1.22 Billion ≈ $13.19 Million	+9.81%
2020-03-31	Rs1.11 Billion ≈ $12.01 Million	+6.28%
2019-03-31	Rs1.04 Billion ≈ $11.30 Million	+6.55%
2018-03-31	Rs980.47 Million ≈ $10.60 Million	-10.80%
2017-03-31	Rs1.10 Billion ≈ $11.89 Million	+11.74%
2016-03-31	Rs983.64 Million ≈ $10.64 Million	+3.08%
2015-03-31	Rs954.26 Million ≈ $10.32 Million	-3.21%
2014-03-31	Rs985.89 Million ≈ $10.66 Million	+0.22%
2013-03-31	Rs983.71 Million ≈ $10.64 Million	-0.10%
2012-03-31	Rs984.69 Million ≈ $10.65 Million	+5.98%
2011-03-31	Rs929.14 Million ≈ $10.05 Million	+6.10%
2010-03-31	Rs875.70 Million ≈ $9.47 Million	+9.23%
2009-03-31	Rs801.68 Million ≈ $8.67 Million	+6.84%
2008-03-31	Rs750.34 Million ≈ $8.11 Million	+3.50%
2007-03-31	Rs724.98 Million ≈ $7.84 Million	+3.22%
2006-03-31	Rs702.35 Million ≈ $7.60 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Jagsonpal Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 148847000000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (March 2025)

Component	Amount	Percentage
Retained Earnings	Rs1.49 Billion	62.03%
Common Stock	Rs132.80 Million	5.53%
Other Comprehensive Income	Rs633.71 Million	26.41%
Other Components	Rs144.52 Million	6.02%
Total Equity	Rs2.40 Billion	100.00%

Jagsonpal Pharmaceuticals Limited Competitors by Market Cap

The table below lists competitors of Jagsonpal Pharmaceuticals Limited ranked by their market capitalization.

Company	Market Cap
Global Lighting Technologies Inc TW:4935	$152.25 Million
Huangshan Tourism Development Co Ltd B SHG:900942	$152.34 Million
Condor Energies Inc. TO:CDR	$152.35 Million
msg life ag HM:MSGL	$152.38 Million
Prospect Resources Ltd AU:PSC	$152.16 Million
Aroa Biosurgery Ltd AU:ARX	$152.13 Million
GOLFZON NEWDIN HOLDINGS Co. Ltd KQ:121440	$152.13 Million
Seritage Growth Properties NYSE:SRG	$152.08 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jagsonpal Pharmaceuticals Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 1,874,020,000 to 2,399,500,000, a change of 525,480,000 (28.0%).
Net income of 553,610,000 contributed positively to equity growth.
Dividend payments of 132,290,000 reduced retained earnings.
Share repurchases of 33,910,000 reduced equity.
New share issuances of 33,910,000 increased equity.
Other comprehensive income increased equity by 44,990,000.
Other factors increased equity by 59,170,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	Rs553.61 Million	+23.07%
Dividends Paid	Rs132.29 Million	-5.51%
Share Repurchases	Rs33.91 Million	-1.41%
Share Issuances	Rs33.91 Million	+1.41%
Other Comprehensive Income	Rs44.99 Million	+1.87%
Other Changes	Rs59.17 Million	+2.47%
Total Change	Rs-	28.04%

Book Value vs Market Value Analysis

This analysis compares Jagsonpal Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 5.90x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has decreased from 19.62x to 5.90x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2006-03-31	Rs10.72	Rs210.37	x
2007-03-31	Rs11.07	Rs210.37	x
2008-03-31	Rs11.46	Rs210.37	x
2009-03-31	Rs12.24	Rs210.37	x
2010-03-31	Rs13.37	Rs210.37	x
2011-03-31	Rs14.19	Rs210.37	x
2012-03-31	Rs15.03	Rs210.37	x
2013-03-31	Rs15.02	Rs210.37	x
2014-03-31	Rs15.06	Rs210.37	x
2015-03-31	Rs14.57	Rs210.37	x
2016-03-31	Rs15.02	Rs210.37	x
2017-03-31	Rs16.78	Rs210.37	x
2018-03-31	Rs14.97	Rs210.37	x
2019-03-31	Rs15.95	Rs210.37	x
2020-03-31	Rs16.95	Rs210.37	x
2021-03-31	Rs18.62	Rs210.37	x
2022-03-31	Rs19.98	Rs210.37	x
2023-03-31	Rs24.26	Rs210.37	x
2024-03-31	Rs28.27	Rs210.37	x
2025-03-31	Rs35.63	Rs210.37	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jagsonpal Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 23.07%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 20.60%
• Asset Turnover: 0.97x
• Equity Multiplier: 1.16x
Recent ROE (23.07%) is above the historical average (7.35%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2006	3.74%	1.69%	1.10x	2.02x	Rs-43.98 Million
2007	3.87%	2.17%	0.88x	2.03x	Rs-44.47 Million
2008	4.10%	2.05%	1.15x	1.74x	Rs-44.27 Million
2009	7.70%	4.53%	1.11x	1.53x	Rs-18.45 Million
2010	10.55%	6.62%	1.13x	1.41x	Rs4.85 Million
2011	7.73%	4.46%	1.18x	1.47x	Rs-21.12 Million
2012	7.57%	4.22%	1.13x	1.59x	Rs-23.90 Million
2013	1.86%	1.10%	1.09x	1.56x	Rs-80.04 Million
2014	2.15%	1.47%	0.92x	1.58x	Rs-77.38 Million
2015	1.23%	0.85%	0.90x	1.62x	Rs-83.71 Million
2016	3.31%	2.27%	0.90x	1.62x	Rs-65.82 Million
2017	10.79%	8.25%	1.01x	1.30x	Rs8.73 Million
2018	-11.78%	-9.13%	0.97x	1.32x	Rs-213.55 Million
2019	6.91%	4.33%	1.23x	1.30x	Rs-32.31 Million
2020	7.09%	4.96%	1.08x	1.32x	Rs-32.33 Million
2021	13.99%	9.08%	1.14x	1.35x	Rs48.65 Million
2022	14.41%	8.67%	1.29x	1.29x	Rs57.69 Million
2023	16.82%	11.29%	1.21x	1.23x	Rs108.32 Million
2024	11.99%	10.76%	0.96x	1.16x	Rs37.23 Million
2025	23.07%	20.60%	0.97x	1.16x	Rs313.66 Million

Industry Comparison

This section compares Jagsonpal Pharmaceuticals Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $41,306,173,573
Average return on equity (ROE) among peers: 11.22%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM)	Rs2.53 Billion	3.74%	0.18x	$152.18 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS)	$83.97 Million	10.78%	0.83x	$27.93 Million
Aarti Drugs Limited (AARTIDRUGS)	$13.69 Billion	12.28%	0.88x	$371.43 Million
Aarti Pharmalabs Limited (AARTIPHARM)	$15.58 Billion	12.42%	0.44x	$725.68 Million
Abbott India Limited (ABBOTINDIA)	$5.44 Billion	22.13%	0.47x	$5.85 Billion
Ajanta Pharma Limited (AJANTPHARM)	$2.98 Billion	25.93%	1.18x	$3.81 Billion
Akums Drugs and Pharmaceutical (AKUMS)	$6.25 Billion	-40.39%	3.91x	$906.19 Million
Alkem Laboratories Limited (ALKEM)	$88.47 Billion	18.60%	0.59x	$6.98 Billion
Amrutanjan Health Care Limited (AMRUTANJAN)	$2.91 Billion	13.70%	0.25x	$178.52 Million
Alembic Pharmaceuticals Limited (APLLTD)	$31.90 Billion	25.98%	0.88x	$1.60 Billion
Aurobindo Pharma Limited (AUROPHARMA)	$245.74 Billion	10.78%	0.38x	$8.73 Billion

About Jagsonpal Pharmaceuticals Limited

NSE:JAGSNPHARM India Drug Manufacturers - Specialty & Generic

Market Cap

$152.18 Million

Rs14.07 Billion INR

Market Cap Rank

#17588 Global

#911 in India

Share Price

Rs210.37

Change (1 day)

+0.74%

52-Week Range

Rs161.07 - Rs292.75

All Time High

Rs761.20